How much money can I get from the Chantix settlement?

Pfizer is paying $44,000,000 to resolve the claims. After attorneys' fees, costs, notice and administration expenses, and any service awards, up to 20% of the net fund is allocated to consumers and the remainder to third-party payors. Each consumer who files a valid claim receives a pro rata share based on the out-of-pocket amount they paid for Chantix, and no consumer's payment will exceed the total they paid. The exact per-person amount depends on how many valid claims are filed.

Do I need proof or receipts to file a Chantix claim?

No documentation is required at the time you file. The consumer Claim Form asks you to state the number of Chantix prescriptions you purchased and your total out-of-pocket cost during the class period; there is no Notice ID or Claim ID to enter. However, the Settlement Administrator may request proof later, so keep records such as an explanation of benefits, pharmacy records, or prescription records showing you paid for Chantix.

What was wrong with Chantix?

Plaintiffs alleged that Pfizer's stop-smoking drug Chantix (varenicline) contained an undisclosed nitrosamine impurity and that Pfizer misrepresented its adherence to current Good Manufacturing Practices. Pfizer denies any wrongdoing and denies violating any law but agreed to the Settlement to avoid the cost and uncertainty of continued litigation. The Court has not decided who is right.

Chantix $44M Settlement: Claim by September 14, 2026

Q: Who qualifies for the Chantix settlement?

You are a Settlement Class Member if you paid any amount of money for retail purchases of Chantix in the United States and its territories from September 29, 2015 through September 17, 2021. Both individual consumers and third-party payors (such as health plans and insurers) are included. Pfizer employees and officers, government actors, anyone whose only purchases fell outside the class period, and anyone who previously opted out are excluded.

Published July 15, 2026

Updated October 20, 2026

The court granted final approval of the $44 million Chantix settlement on October 14, 2026. The claim deadline was September 14, 2026; people who filed a valid claim share the consumer pool pro rata once the settlement takes effect and claims are processed.

Pfizer will pay $44 million to resolve claims that its stop-smoking drug Chantix contained an undisclosed nitrosamine impurity. Pfizer denies any wrongdoing.

By Steve Levine

Editor-in-Chief

Current Status

Judge Katherine Polk Failla granted final approval of the settlement on October 14, 2026, the day after the October 13 fairness hearing, and dismissed the claims against Pfizer with prejudice. The judgment notes there were no objections to the settlement or the allocation plan and one request for exclusion. The claim deadline was September 14, 2026, so no new claims can be filed. People who submitted a valid claim will be paid after the settlement's Effective Date and the administrator's claim review; no payment date has been announced.

What Changed?

On October 13, 2026 the court awarded class counsel $14,666,666.67 in attorneys' fees (one-third of the fund) and $144,340.20 in litigation expenses, plus service awards of $15,000 to each third-party-payor plaintiff and $5,000 to each consumer plaintiff. On October 14 it entered the Judgment and Order Granting Final Approval. In its September 28 report to the court, settlement administrator A.B. Data said it had received 3,581,486 consumer claims and 17,885 third-party-payor claims, none of which had yet been fully reviewed.

What Is This Settlement About?

Pfizer, Inc. has agreed to pay $44,000,000 to settle a putative class action claiming that its branded stop-smoking drug Chantix (varenicline) contained an undisclosed nitrosamine impurity and that Pfizer misrepresented its adherence to current Good Manufacturing Practices in making the drug. The case is In re Chantix (Varenicline) Marketing, Sales Practices and Products Liability Litigation (No. II), No. 22-MD-3050 (KPF), before Judge Katherine Polk Failla in the U.S. District Court for the Southern District of New York.

Pfizer believes it did nothing wrong and denies violating any law. It agreed to the Settlement to avoid the uncertainties and expenses of continued litigation, and the Court has not decided who is right. The Court granted preliminary approval on June 1, 2026, notice went out to the class in July 2026, the claim deadline was September 14, 2026, and the Court granted final approval on October 14, 2026.

Free settlement alerts

Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.

Status Claims Closed Final approval granted October 14, 2026 · claims under review

Claim Deadline September 14, 2026 Submit online or postmark by this date · same date to exclude or object

Estimated Payout Pro rata cash Based on what you paid out of pocket for Chantix · consumer pool is up to 20% of the net $44M fund

Proof Required No Self-report your prescriptions & out-of-pocket cost · no Notice ID or Claim ID · keep pharmacy records in case the administrator asks

Who Qualifies?

The Settlement Class includes all individuals and third-party payors who paid any amount of money for retail purchases of Chantix in the United States and its territories from September 29, 2015 through September 17, 2021. If you filled a Chantix prescription and paid anything toward it during that window — a copay, coinsurance, or a deductible amount — you are covered.

Several groups are excluded and cannot file a claim, even if they otherwise fit the definition: any officer, director, manager, or employee of Pfizer; government agencies or governmental actors, including any state Attorney General office; anyone whose only Chantix purchases fell before September 29, 2015 or after September 17, 2021; and anyone who previously opted out of the Settlement Class in this case.

The Settlement covers only Pfizer-brand Chantix, not generic varenicline made by other manufacturers. There are two ways to claim: an Individual Consumer Claim Form for people who paid out of pocket, and a separate Third-Party Payor Claim Form for health plans, insurers, and other entities that paid or reimbursed for Chantix. Use the form that matches who you are.

How Much Can You Get?

Pfizer is paying a total of $44,000,000. After the Court deducts attorneys' fees, litigation expenses, notice and administration costs, and any class representative service awards, the remaining net fund is split: up to 20% goes to the consumer class, and the rest goes to third-party payors.

Each consumer who submits a valid claim receives a pro rata share of the consumer pool, calculated from the out-of-pocket amount they paid for Chantix during the class period. No consumer's payment will be more than the total they actually paid for the drug. Third-party payors are paid pro rata from the remainder based on their qualifying, documented payments. Because payments are pro rata, the exact per-person amount will not be known until all valid claims are counted after the deadline.

What the claim count means for payments (OCA estimate). After the $14,666,666.67 fee award and $144,340.20 in expenses, the net fund is at most about $29.19 million before notice and administration costs and service awards are taken out. Consumers' share is capped at 20% of the net fund, so the consumer pool is at most about $5.84 million. Spread across the 3,581,486 consumer claims the administrator reported on September 28, that works out to an average of no more than about $1.63 per claim. Actual payments will differ: each consumer's share is based on what they paid out of pocket, and the administrator is still screening claims for duplicates and ineligibility, which could shrink the number that are paid. This is OpenClassActions.com arithmetic from the court filings, not a figure from the settlement administrator.

Payments are sent digitally by default, so the claim form asks for a valid email address and mobile phone number unless you affirmatively choose another payment method.

How to File a Claim

You can file online through the official settlement website, ChantixSettlement.com, or download a paper Claim Form and mail it so it is postmarked by the deadline. Consumers should use the Consumer Claim Form; third-party payors should use the TPP Claim Form and submit supporting claims data.

On the consumer form you confirm you are a class member, then provide the number of Chantix prescriptions you purchased and your total out-of-pocket cost from September 29, 2015 through September 17, 2021. You do not need to attach documentation when you file, but the Settlement Administrator may ask for proof later — an explanation of benefits from your insurer, pharmacy records, or copies of prescription records showing you paid for Chantix. Keep those records until your payment arrives.

Your Other Options and Key Dates

Class members who did nothing will not receive a payment and gave up their right to sue Pfizer over the claims in this case. The deadline to exclude yourself (opt out) or object was September 14, 2026; the Court's final judgment records one exclusion request and no objections. The Court held its Final Approval Hearing on October 13, 2026 and granted final approval the next day.

Be cautious of any website other than the official one presenting a "Chantix claim form." The Settlement is administered by A.B. Data, Ltd. under the supervision of Class Counsel, and the only official site is ChantixSettlement.com. This page is informational and is not legal advice — do not stop a prescribed medication because of a settlement.

For background on the underlying litigation — the 2021 recall and the consolidated cases that led here — see our explainer on the Chantix varenicline nitrosamine MDL. If you paid for common generic drugs in recent years, you may also qualify for the separate generic drug price-fixing settlements.

Frequently Asked Questions

Who qualifies for the Chantix settlement?

Anyone who paid any amount for retail purchases of Chantix in the United States and its territories from September 29, 2015 through September 17, 2021. Both individual consumers and third-party payors (health plans, insurers) are included. Pfizer insiders, government actors, people whose only purchases fell outside the class period, and prior opt-outs are excluded.

Do I need receipts to file?

No documentation is required when you file. You self-report the number of prescriptions and your out-of-pocket cost, and there is no Notice ID or Claim ID to enter. The Settlement Administrator may request proof later, so keep an explanation of benefits, pharmacy records, or prescription records showing you paid for Chantix.

How much will I receive?

Each valid consumer claim gets a pro rata share of the consumer pool (up to 20% of the net $44 million fund), based on what you paid out of pocket, capped at your total spend. Because it is pro rata, the exact amount depends on how many valid claims are filed.

What is the deadline?

The claim deadline was September 14, 2026, which was also the deadline to opt out or object. The Court held the Final Approval Hearing on October 13, 2026 and granted final approval on October 14, 2026, so no new claims can be filed.

Official Settlement Notice & Claim Form

Sources

• Official Chantix Settlement website (A.B. Data, Ltd., administrator): ChantixSettlement.com
• Judgment and Order Granting Final Approval of Class Action Settlement (ECF No. 152, filed October 14, 2026) and Order Awarding Attorneys' Fees, Reimbursement of Expenses, and Service Awards (ECF No. 153, filed October 13, 2026), posted on the official settlement website's Court Documents page
• Declaration of Marie A. Christine of A.B. Data (ECF No. 146, filed September 28, 2026) — notice, exclusion and claim counts
• CourtListener — docket for In re Chantix (Varenicline)…, No. 1:22-md-03050 (S.D.N.Y.): CourtListener Docket
• U.S. Food and Drug Administration — nitrosamine in varenicline (Chantix) updates: FDA Nitrosamine / Varenicline Updates

For more class actions keep scrolling below.

Settlement Amount $44,000,000

Case Title In re Chantix (Varenicline) Marketing, Sales Practices and Products Liability Litigation (No. II)

Case Number 22-MD-3050 (KPF) · 22-MC-3050

Court U.S. District Court, S.D.N.Y. · Judge Katherine Polk Failla

Final Approval Granted October 14, 2026 after the October 13, 2026 fairness hearing

Administrator A.B. Data, Ltd.

Official Website Chantix Settlement.com

Chantix $44 Million Class Action Settlement: Who Qualifies and How to Claim by September 14, 2026